Caprotec Bioanalytics GmbH

This method, called Capture Compound Mass Spectrometry (CCMS), is of fundamental importance and general applicability in the areas of proteome research (the study of protein building blocks in cells and tissue) and the analysis of small molecule ?protein interactions. One main application for which this knowledge is important is the study of side effects and toxicity of active pharmaceutical ingredients.

The CCMS technology is using so called Capture Compounds? trifunctional molecules that are detecting, binding and isolating proteins for the purpose of subsequent identification. For many applications, CCMS is clearly superior to conventional methods and is thus closing a technology gap in the scientific field of proteome research. CCMS is complementing widely used technologies such as 2D gelelectrophoresis and affinity chromatography.

caprotec is marketing the CCMS technology as ready-to-use reagent sets (caproKits? for basic research applications in academia and collaborative projects (ImproMed? with pharmaceutical companies. The main goals of these collaborations are increased drug safety through investigation and prevention of serious side effects and drug toxicity.

Founded in 2006 by scientist and entrepreneur Prof. Dr. Hubert K?ter, caprotec raised approx. 9 million US $ during 2007. Lead investors are the IBB Beteiligungsgesellschaft mbH, the KfW Mittelstandsbank and Creathor Venture Management. The company? headquarters are located in Berlin-Adlershof, where new facilities and laboratories were opened in January of 2008. Currently, caprotec bioanalytics GmbH has 23 full-time employees.

The company has already several distribution agreements in place, covering regions in Asia and Southern-Europe. In addition caprotec Inc. located in Burlington, MA was opened in July 2009 to provide sales, marketing and customer support functions for North America.